Browsing Tag
Pascal Soriot
18 posts
AstraZeneca FY2025 results analysis: How oncology scale, China exposure, and pipeline depth are reshaping long-term earnings power
AstraZeneca’s FY2025 results reveal what’s driving growth, where risks are building, and how pipeline depth could shape earnings beyond 2030. Read the full analysis.
AstraZeneca strikes $50bn U.S. deal to lower drug prices while reshoring manufacturing amid tariff freeze
AstraZeneca inks $50B U.S. deal to cut drug prices and boost onshore manufacturing. See what this means for patients, profits, and pharma’s policy future.
AstraZeneca’s $13.6bn Q1 2025 sales surge as cancer drugs and AI deals set stage for $80bn goal
Explore how AstraZeneca’s strong Q1 2025 results, new drug approvals, and AI-powered R&D are reshaping its global growth story.
AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing
AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy.
AstraZeneca reports strong FY 2024 results with robust revenue growth driven by oncology and biopharmaceuticals
AstraZeneca’s financial performance for fiscal year 2024 reflects impressive growth, with the pharmaceutical giant reporting a 21% surge…
AstraZeneca to expand Canadian operations with $570m investment
AstraZeneca, a leading global pharmaceutical company, has announced a C$820 million (US$570 million) investment in Canada, marking a…
AstraZeneca to bolster US footprint with multi-billion dollar strategy
In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment…
AstraZeneca achieves remarkable financial growth in 2023, fueling optimism for future innovations
AstraZeneca PLC unveiled its financial results for the fiscal year and fourth quarter of 2023 on 8 February…
AstraZeneca launches Evinova to optimize clinical trials and patient care
AstraZeneca has announced the launch of Evinova, poised to become a leading provider in the digital health solutions…
AstraZeneca reports steady growth in 9M and Q3 2023 with core EPS increase
AstraZeneca has announced its financial results for the nine months (9M) and third quarter (Q3) of 2023, displaying…